LPL Financial LLC grew its holdings in LifeVantage Co. (NASDAQ:LFVN - Free Report) by 301.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 211,039 shares of the company's stock after purchasing an additional 158,405 shares during the quarter. LPL Financial LLC owned approximately 1.68% of LifeVantage worth $3,700,000 at the end of the most recent quarter.
Other institutional investors have also recently modified their holdings of the company. Copeland Capital Management LLC purchased a new position in LifeVantage during the fourth quarter worth about $65,000. Hillsdale Investment Management Inc. grew its holdings in shares of LifeVantage by 7.3% during the 4th quarter. Hillsdale Investment Management Inc. now owns 14,720 shares of the company's stock worth $258,000 after purchasing an additional 1,000 shares during the period. Barclays PLC raised its holdings in LifeVantage by 38.2% in the third quarter. Barclays PLC now owns 41,966 shares of the company's stock valued at $507,000 after buying an additional 11,608 shares during the period. HighTower Advisors LLC purchased a new stake in LifeVantage during the third quarter worth approximately $638,000. Finally, Ritholtz Wealth Management increased its position in shares of LifeVantage by 65.2% in the fourth quarter. Ritholtz Wealth Management now owns 47,348 shares of the company's stock worth $830,000 after acquiring an additional 18,682 shares in the last quarter. 35.32% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other LifeVantage news, Director Raymond B. Greer sold 8,000 shares of the business's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $20.15, for a total transaction of $161,200.00. Following the sale, the director now owns 99,288 shares in the company, valued at approximately $2,000,653.20. The trade was a 7.46 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 20.65% of the stock is owned by insiders.
LifeVantage Stock Performance
Shares of NASDAQ:LFVN traded up $0.19 during trading on Wednesday, hitting $14.67. The company's stock had a trading volume of 6,625 shares, compared to its average volume of 124,150. LifeVantage Co. has a fifty-two week low of $5.22 and a fifty-two week high of $27.38. The stock's 50-day moving average price is $16.25 and its two-hundred day moving average price is $16.28. The company has a market capitalization of $184.06 million, a PE ratio of 26.19 and a beta of 0.75.
LifeVantage (NASDAQ:LFVN - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.08. LifeVantage had a net margin of 3.46% and a return on equity of 34.29%.
LifeVantage Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 17th. Investors of record on Monday, March 3rd were paid a dividend of $0.04 per share. The ex-dividend date was Monday, March 3rd. This represents a $0.16 annualized dividend and a yield of 1.09%. LifeVantage's dividend payout ratio (DPR) is 28.57%.
Analysts Set New Price Targets
LFVN has been the subject of several recent research reports. Craig Hallum started coverage on LifeVantage in a report on Tuesday, January 14th. They issued a "buy" rating and a $35.00 price target for the company. Lake Street Capital assumed coverage on LifeVantage in a research report on Thursday, December 19th. They set a "buy" rating and a $26.00 price target on the stock.
Get Our Latest Stock Report on LFVN
About LifeVantage
(
Free Report)
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.
Read More
Before you consider LifeVantage, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeVantage wasn't on the list.
While LifeVantage currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
